Volume 14, Issue 5 (July 2020)                   Qom Univ Med Sci J 2020, 14(5): 49-58 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Asa E, Janatifar R, Alavisoltani M, Verdi A, Janbazi M. Effect of Alpha-Lipoic Acid on Blood Hormonal Parameters and Follicular Fluid Oxidative Stress Factors in Infertile Women with Polycystic Ovary Syndrome Undergoing Intracytoplasmic Sperm Injection. Qom Univ Med Sci J 2020; 14 (5) :49-58
URL: http://journal.muq.ac.ir/article-1-2805-en.html
1- Department of Reproductive Biology, Academic Center for Education, Culture and Research (ACECR), Qom, Iran. , asa.elham@gmail.com
2- Department of Reproductive Biology, Academic Center for Education, Culture and Research (ACECR), Qom, Iran.
Abstract:   (3231 Views)
Background and Objectives: Alpha-Lipoic Acid (ALA) is a dietary supplement with antioxidant and anti-inflammatory properties. The present study aimed to evaluate the effect of alpha-lipoic acid on hormonal parameters of blood plasma serum and follicular fluid oxidative stress factors in infertile women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection.
 
Methods: Patients were selected from infertile women with polycystic ovary syndrome within the age range of 35-35 referring to Qom University Jihad Infertility Treatment Center. Patients were randomly assigned to treatment and control groups. The control group received 1500 mg metformin daily, whereas the treatment group received 600 mg alpha-lipoic acid with 1500 mg metformin(MET) daily for 8 weeks. Thereafter, anthropometric characteristics, blood glucose, plasma serum hormonal parameters, and follicular fluid oxidative stress factors were measured. Independent t-test and paired t- test were used to analyze the data if it was normal, and the Mann-Whitney U test was utilized if the samples were not normal.
 
Results: Glucose and insulin levels were significantly reduced in the ALA treatment group (P<0.05). LH also showed a significant decrease in the ALA treatment group (P <0.05); nonetheless, the levels of Follicle-Stimulating Hormone (FSH), testosterone, and estradiol did not change (P<0.05). A significant difference was observed between the control and treatment groups in terms of oxidative stress markers (MDA and TAC) (P<0.05).
 
Conclusion: As evidenced by the obtained results, ALA+MET consumption is effective in the reduction of oxidative stress, glucose, insulin, and LH levels. This property can be used to prevent complications of this disease, including hyperglycemia and hormonal imbalance.

Full-Text [PDF 993 kb]   (616 Downloads)    
Type of Study: Original Article | Subject: فیزیولوژی
Received: 2020/04/28 | Accepted: 2020/08/23 | Published: 2020/07/31

References
1. 1. Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 2008;60(1):39-51. PMID: 18277351
2. Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine 2006;30(1):19-26. PMID: 17185788 [DOI:10.1385/ENDO:30:1:19]
3. DuRant EM, Leslie NS, Critch EA. Managing polycystic ovary syndrome: a cognitive behavioral strategy. Nurs Womens Health 2009;13(4):292-300. PMID: 19686552 [DOI:10.1111/j.1751-486X.2009.01439.x]
4. Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab 2007;18(7):273-9. Link [DOI:10.1016/j.tem.2007.08.001]
5. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91(11):4237-45. PMID: 16940456 [DOI:10.1210/jc.2006-0178]
6. Ruby LA. Polycystic ovarian syndrome: an evidence-based approach to reducing metabolic consequences. J Nurse Practitioners 2008;4(9):697-704. Link [DOI:10.1016/j.nurpra.2008.08.005]
7. Sharma A, Atiomo W. Recent developments in polycystic ovary syndrome. Curr Obstet Gynaecol 2003;13(5):281-6. Link [DOI:10.1016/S0957-5847(03)00050-7]
8. Dewailly D. Diagnostic criteria for PCOS: is there a need for a rethink? Best Pract Res Clin Obstet Gynaecol 2016;37:5-11. PMID: 27151631 [DOI:10.1016/j.bpobgyn.2016.03.009]
9. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 2011;9(1):39. PMID: 21435276 [DOI:10.1186/1477-7827-9-39]
10. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97(1):28-38.e25. PMID: 22153789 [DOI:10.1016/j.fertnstert.2011.09.024]
11. Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev 2016;2016:8589318. PMID: 26770659 [DOI:10.1155/2016/8589318]
12. Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26(2):251-82. PMID: 15561799 [DOI:10.1210/er.2004-0004]
13. Papalou O, Victor VM, Diamanti-Kandarakis E. Oxidative stress in polycystic ovary syndrome. Curr Pharm Des 2016;22(18):2709-22. PMID: 26881435 [DOI:10.2174/1381612822666160216151852]
14. Huerta AE, Fernández-Galilea M, Prieto-Hontoria PL, Martínez JA, Moreno-Aliaga MJ. Alpha-lipoic acid: a dietary supplement with therapeutic potential for obesity and related metabolic diseases. Nonvitamin and nonmineral nutritional supplements. Massachusetts: Academic Press; 2019. Link [DOI:10.1016/B978-0-12-812491-8.00011-4]
15. Mendoza-Núñez VM, García-Martínez BI, Rosado-Pérez J, Santiago-Osorio E, Pedraza-Chaverri J, Hernández-Abad VJ, et al. The effect of 600 mg alpha-lipoic acid supplementation on oxidative stress, inflammation, and RAGE in older adults with type 2 diabetes mellitus. Oxid Med Cell Longev 2019;2019:3276958. PMID: 31285784 [DOI:10.1155/2019/3276958]
16. Yeh JI, Gulve EA, Rameh L, Birnbaum MJ. The effects of wortmannin on rat skeletal muscle dissociation of signaling pathways for insulin-and contraction-activated hexose transport. J Biol Chem 1995;270(5):2107-11. PMID: 7836438 [DOI:10.1074/jbc.270.5.2107]
17. Piltonen TT, Giacobini P, Edvinsson A, Hustad S, Lager S, Morin-Papunen L, et al. Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term. Fertil Steril 2019;111(3):588-96.e1. PMID: 30630591 [DOI:10.1016/j.fertnstert.2018.11.028]
18. Cheraghi E, Mehranjani MS, Shariatzadeh MA, Esfahani MH, Ebrahimi Z. Co-administration of metformin and N-acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. Int J Fertil Steril 2014;8(2):119-28. PMID: 25083175
19. Genazzani A, Despini G, Santagni S, Prati A, Rattighieri E, Chierchia E, et al. Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol Metab Synd 2014;3(140):2161-71. Link [DOI:10.4172/2161-1017.1000140]
20. Ebada MA, Fayed N, Fayed L, Alkanj S, Abdelkarim A, Farwati H, et al. Efficacy of alpha-lipoic acid in the management of diabetes mellitus: a systematic review and meta-analysis. Iran J Pharm Res 2019;18(4):2144-56. PMID: 32184879 [DOI:10.2174/1871527318666190314101314]
21. Mehrafza M, Raoufi A, Abdollahian P, Nikpouri Z, Nasiri M, Hosseini A. In vitro fertilization outcome in patients with polycystic ovary syndrome treated with GnRH analogue. Tehran Univ Med J 2013;71(8):518-23. Link
22. Cheraghi E, Mehranjani MS, Shariatzadeh MA, Esfahani MH, Ebrahimi ZJ. N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reprod Fertil Dev 2016;28(6):723-31. PMID: 25482371 [DOI:10.1071/RD14182]
23. Genazzani AD, Prati A, Simoncini T, Napolitano A. Modulatory role of D-chiro-inositol and alpha lipoic acid combination on hormonal and metabolic parameters of overweight/obese PCOS patients. Eur Gynecol Obstet 2019;1:29-33. Link
24. Foroozandeh M, Hosseini S. Effects of metformin and ginger rhizome extract on the pituitary-gonad function in adult female rats with polycystic ovary syndrome. Armaghane Danesh 2017;22(3):337-49. Link
25. Genazzani A, Shefer K, Della Casa D, Prati A, Napolitano A, Manzo A, et al. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest 2018;41(5):583-90. PMID: 29090431 [DOI:10.1007/s40618-017-0782-z]
26. Lu CC, Chiang JH, Tsai FJ, Hsu YM, Juan YN, Yang JS, et al. Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling. Int J Oncol 2019;54(4):1271-81. PMID: 30720062 [DOI:10.3892/ijo.2019.4704]
27. Han G, Gong H, Wang Y, Guo S, Liu K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther 2015;16(1):77-87. PMID: 25456211 [DOI:10.4161/15384047.2014.987021]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Qom University of Medical Sciences Journal

Designed & Developed by : Yektaweb